PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un podcast de American College of Cardiology - Les mardis
Catégories:
In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit. In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
